Researcher
Alfons Verbruggen
- Disciplines:Medicinal products, Biomarker discovery and evaluation, Drug discovery and development, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Faculty of Pharmaceutical Sciences (Faculty)
Member
From1 Oct 2020 → Today - Radiopharmaceutical Research (Division)
Member
From1 Oct 1999 → 30 Sep 2019
Projects
1 - 10 of 10
- translational study of the modulation of fosfodiesterase type 10A expression by dopaminergic neurotransmission using molecular imagingFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Oncocidia_the novel anticancer therapy: phase 0 clinical study.From1 Jan 2013 → 31 Dec 2013Funding: IOF - Industrial Research Fund
- Development and evaluation of PET ligands for the in vivo visualisation of phosphodiesterase type 5 (PDE5).From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Synthesis and biological evaluation of carbon-11 and fluorine-18 labelled P2X7-receptor ligands for diagnosis of neurological diseases using positron emission tomographyFrom1 Oct 2011 → 30 Sep 2015Funding: FWO fellowships
- In vivo molecular imaging research (IMIR).From1 Nov 2010 → 31 Oct 2018Funding: BOF - Concerted Research Project from 1994
- Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application.From1 Oct 2010 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Preclinical validation and first in man study of PET radioligands for the cannabinoidreceptor type 2.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Synthesis and (pre)clinical evaluation of PET radioligands for in vivo visualization of phosphodiesterase 10, an enzyme involved in neurological and psychiatric disorders.From1 Oct 2009 → 30 Sep 2010Funding: BOF - Other initiatives
- Development of a radiolabelled probes for the in vivo visualisation of the TRPV1 receptor with PETFrom1 Oct 2008 → 24 Jan 2013Funding: IWT personal funding - strategic basic research grants
- Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag.From1 Jul 2008 → 30 Jun 2009Funding: IOF - Industrial Research Fund
Publications
41 - 50 of 124
- Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planning(2013)
Authors: Geert Maleux, Kristof Baete, Chris Verslype, Karin Haustermans, Alfons Verbruggen, Eric Van Cutsem, Christophe Deroose
Pages: 940 - 2 - Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A(2013)
Authors: Sofie Celen, Michel Koole, Maarten Ooms, Alfons Verbruggen, Koen Van Laere, Guy Bormans
Pages: 13 - 22 - Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats(2013)
Authors: Marlein Miranda Cona, YUanbo Feng, Alfons Verbruggen, Raymond Oyen, Yicheng Ni
Pages: 1434 - 1449 - Comparative study of Iodine-123-labeled-hypericin and Tc-99m-labeled-hexakis [2-methoxyisobutylisonitril] in a rabbit model of myocardial infarction(2013)
Authors: Marlein Miranda Cona, YUanbo Feng, Kathleen Vunckx, Lin Zhou, Ahmadreza Rezaei, Olivier Gheysens, Johan Nuyts, Alfons Verbruggen, Raymond Oyen, Yicheng Ni
Pages: 304 - 311 - Whole-Body Biodistribution and Radiation Dosimetry of the Cannabinoid Type 2 Receptor Ligand [(11)C]-NE40 in Healthy Subjects(2013)
Authors: Rawaha Ahmad, Michel Koole, Alfons Verbruggen, Guy Bormans, Koen Van Laere
Pages: 384 - 90 - Synthesis and biological evaluation of (68)Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis(2013)
Authors: Natalia Dyubankova, Eveline Lescrinier, Yicheng Ni, Guy Bormans, Alfons Verbruggen
Pages: 816 - 822 - A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [iodogen] dissolved in dimethyl sulphoxide (DMSO)(2013)
Authors: Marlein Miranda Cona, Junjie Li, Feng Chen, YUanbo Feng, Yeranddy Aguiar Alpizar, Florent Vanstapel, Karel Talavera Pérez, Peter de Witte, Alfons Verbruggen, Raymond Oyen, et al.
Pages: 730 - 737 - Synthesis and biological evaluation of 68Ga labeled bis-DOTA-3,3'-(benzylidene)-bis-(1H-indole-2-carbohydrazide) as a PET tracer for in vivo visualization of necrosis(2013)
Authors: Marlein Miranda Cona, Natalia Dyubankova, Eveline Lescrinier, Guy Bormans, Yicheng Ni, Alfons Verbruggen
Pages: 3216 - 3220 - In vitro and in vivo comparison of 18F and 123I-labeled ML10 with 68Ga-Cys2-AnxA5 for molecular imaging of apoptosis(2013)
Authors: Matthias Bauwens, Stijn Hendrickx, Yicheng Ni, Luc Mortelmans, Felix Mottaghy, Alfons Verbruggen
Pages: 187 - 200 - Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type-1 receptors(2013)
Authors: Alfons Verbruggen, Guy Bormans
Pages: 207 - 214
Patents
1 - 4 of 4